MSB 3.16% $1.31 mesoblast limited

Ann: CEO Presentation to 2023 Annual General Meeting, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,474 Posts.
    lightbulb Created with Sketch. 479
    Pretty impressive meeting with SI smashing all with data.

    Well done all who asked questions

    Huge positive results for Revascor PRDD from randomised control trial. (Publication coming out very soon )…
    Same with Back

    Very confident in SR- aGVHD.

    Very confident in Adult aGVHD.



    Cells work!

    Money - chasing partnership , cannot predict, back pain and Heart space partners looking good…Advanced but seems dependant on FDA tick.

    FDA wants improved potency assay. Product is consistent. Hopefully , should be enough to release product with children.

    Parallel strategy going on. Next meeting , next quarter ..

    Thanks for asking about availability to children.. VERY IMPORTANT ANSWER. THEY ARE .Cells work. Parents, doctors Kids everyone sees the value… WHY NOT FDA. Why holding up approval….

    Again , whoever asked the question, please let me know but thanks..

    ok… i have to head back to work so ill post this
    Last edited by Kerebrad: 28/11/23
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.